These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

560 related articles for article (PubMed ID: 16144528)

  • 21. Dendritic cell vaccines for the treatment of prostate cancer.
    Lehrfeld TJ; Lee DI
    Urol Oncol; 2008; 26(6):576-80. PubMed ID: 18996314
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Immunotherapy of metastasis.
    Dallal RM; Lotze MT
    Surg Oncol Clin N Am; 2001 Apr; 10(2):433-47, xi. PubMed ID: 11382596
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Changes of dendritic cells in prostate cancer and dendritic cell-based immunotherapy].
    Qi SY; Wang M; Xu Y
    Zhonghua Nan Ke Xue; 2007 May; 13(5):453-6. PubMed ID: 17569266
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Dendritic-cell vaccination for prostate cancer.
    Thomas-Kaskel AK; Veelken H
    Immunotherapy; 2009 Jan; 1(1):63-72. PubMed ID: 20635974
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Pilot trial of vaccines based on autologous dendritic cells loaded in vitro with tumor antigens in the treatment of cancer of the urinary bladder].
    Shoua AB; Sergienco NF; Sitnikov NV; Chkadua GZ
    Urologiia; 2008; (5):54-7. PubMed ID: 19069498
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Recent advances and hurdles in melanoma immunotherapy.
    Jandus C; Speiser D; Romero P
    Pigment Cell Melanoma Res; 2009 Dec; 22(6):711-23. PubMed ID: 19735459
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Future directions in bladder cancer immunotherapy: towards adaptive immunity.
    Smith SG; Zaharoff DA
    Immunotherapy; 2016; 8(3):351-65. PubMed ID: 26860539
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Dendritic cells: tools and targets for antitumor vaccination.
    den Brok MH; Nierkens S; Figdor CG; Ruers TJ; Adema GJ
    Expert Rev Vaccines; 2005 Oct; 4(5):699-710. PubMed ID: 16221071
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Vaccines for immunotherapy of breast cancer and prostate cancer: new developments and comparative aspects.
    Minev BR; Guo F; Gueorguieva I; Kaiser HE
    In Vivo; 2002; 16(6):405-15. PubMed ID: 12494883
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Immunesurveillance by dendritic cells: potential implication for immunotherapy of endocrine cancers.
    Schott M
    Endocr Relat Cancer; 2006 Sep; 13(3):779-95. PubMed ID: 16954430
    [TBL] [Abstract][Full Text] [Related]  

  • 31. CpG therapy is superior to BCG in an orthotopic bladder cancer model and generates CD4+ T-cell immunity.
    Mangsbo SM; Ninalga C; Essand M; Loskog A; Tötterman TH
    J Immunother; 2008 Jan; 31(1):34-42. PubMed ID: 18157010
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Recent advances in immunotherapy for human glioma.
    Carpentier AF; Meng Y
    Curr Opin Oncol; 2006 Nov; 18(6):631-6. PubMed ID: 16988586
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Bacillus Calmette-Guérin-pulsed dendritic cells stimulate natural killer T cells and gammadeltaT cells.
    Naoe M; Ogawa Y; Takeshita K; Morita J; Iwamoto S; Miyazaki A; Yoshida H
    Int J Urol; 2007 Jun; 14(6):532-8; discussion 538. PubMed ID: 17593099
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Neutrophil granulocytes are required for effective Bacillus Calmette-Guérin immunotherapy of bladder cancer and orchestrate local immune responses.
    Suttmann H; Riemensberger J; Bentien G; Schmaltz D; Stöckle M; Jocham D; Böhle A; Brandau S
    Cancer Res; 2006 Aug; 66(16):8250-7. PubMed ID: 16912205
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Role of animal models in understanding intravesical therapy with bacille Calmette-Guérin.
    Ratliff TL
    Clin Infect Dis; 2000 Sep; 31 Suppl 3():S106-8. PubMed ID: 11010834
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Dendritic cell-based cancer immunotherapies.
    Fujii S; Takayama T; Asakura M; Aki K; Fujimoto K; Shimizu K
    Arch Immunol Ther Exp (Warsz); 2009; 57(3):189-98. PubMed ID: 19479202
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Molecular research in cancer: future clinical applications.
    Ratliff TL
    Acta Urol Belg; 1996 May; 64(2):53-5. PubMed ID: 8701813
    [No Abstract]   [Full Text] [Related]  

  • 38. Combinational adenovirus-mediated gene therapy and dendritic cell vaccine in combating well-established tumors.
    Xia D; Moyana T; Xiang J
    Cell Res; 2006 Mar; 16(3):241-59. PubMed ID: 16541123
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Dendritic cells as therapeutic vaccines against cancer.
    Banchereau J; Palucka AK
    Nat Rev Immunol; 2005 Apr; 5(4):296-306. PubMed ID: 15803149
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Current immunotherapeutic strategies in prostate cancer.
    Grosso JF; Drake CG
    Surg Oncol Clin N Am; 2007 Oct; 16(4):861-71, x. PubMed ID: 18022549
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 28.